195 Diagnostic utility of molecular and imaging biomarkers 2 Table 43. Test performance of microRNA analysis in indeterminate thyroid nodules (validation sets) reference ni, validation set TP FP FN TN malignant (TP+FN/ni) sensitivity (95% CI), % specificity (95% CI), % LR+ (95% CI) LR- (95% CI) Agretti 2012 53 9 16 6 22 28% 60 (32-84) 58 (41-74) 1.43 (0.82-2.49) 0.69 (0.35-1.36) Keutgen 2012 72 22 7 0 43 31% 100 (85-100) 86 (73-94) 6.65 (3.43-12.92) 0.03 (0.00-0.40 Shen 2012 30 7 4 4 15 37% 64 (31-89) 79 (54-94) 3.02 (1.14-8.04) 0.46 (0.20-1.04) Vriens 2012 125 n.s. n.s. n.s. n.s. 30%* n.a. n.a. n.a. n.a. Labourier 2015 109 20 6 15 68 32% 57 (39-74) 92 (83-97) 7.05 (3.11-15.98) 0.47 (0.32-0.69) Rossi 2016 27 14 0 0 13 52% 100 (77-100) 100 (75-100) 27.07 (1.78-412.31) 0.03 (0.00-0.53) TOTAL 416 *: data extracted from original article. FN: false negative. FP: false positive. LR+: positive likelihood ratio. LR-: negative likelihood ratio. ni : number of indeterminate nodules. TN: true negative. TP: true positive.
RkJQdWJsaXNoZXIy MTk4NDMw